

Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India

- Zydus will market the product under the brand names – SEMAGLYN™, MASHEMA™ and ALTERME™
- Lupin will market the product under the brand names Semanext® and Lupin's Livarise®
- Partnership aims to strengthen patient access for advanced diabetes and weight management therapies

Ahmedabad, India, 17 March, 2026

Zydus Lifesciences Limited (Zydus), an innovation-led life-sciences company with subsidiaries/affiliates in India and across the globe, has entered into a Licensing and Supply Agreement with global pharma major, Lupin Limited (Lupin) to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India. This partnership brings together Zydus' strong product development capabilities and Lupin's extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under the brand names Semanext® and Lupin's Livarise®. Zydus will market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™. Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, "Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients' needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India."

Nilesh Gupta, Managing Director, Lupin, said, " Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India."

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy, when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes

It is also indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

About Zydus Lifesciences Limited

Zydus Lifesciences Limited is an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a strong international presence across the United States, India, and other global markets. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in research and development. The company is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

For more details, please visit: www.zyduslife.com

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

For further information or queries, please contact:

Zydus

Media:

Sujatha Rajesh

Email: sujatha.rajesh@zyduslife.com

Mobile: 9974051180

Investors:

Arvind Bothra

Email: arvind.bothra@zyduslife.com

Mobile: 9833853107

Lupin:

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

Email: rajalakshmi.azariah@lupin.com